|Bid||27.16 x 800|
|Ask||27.72 x 800|
|Day's range||26.34 - 27.33|
|52-week range||10.61 - 33.23|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||127.89|
|Earnings date||06 May 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||27.00|
PPD, Inc. Announces Pricing and Upsizing of Senior Notes Offering
PPD has been recognized for excellence in clinical research by pharmaceutical and biotech professionals surveyed for 2020 CRO Leadership Awards.
PPD extended its digital clinical trial solutions to support biopharma companies’ research continuity initiatives and to help ensure patient safety.
Accelerated Enrollment Solutions launches new program to help biopharmaceutical companies maintain business continuity during global COVID-19 pandemic
AES and Science 37 collaborating to recruit and enroll clinical trial participants who live beyond geographic locations of traditional research sites
PPD today announced the cancellation of its fireside chat and related webcast at the Barclays Global Healthcare Conference
PPD, a leading global contract research organization, today reported its financial results for the fourth quarter and full year ended Dec. 31, 2019